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Abstract
Background: Alport syndrome is a clinically heterogeneous nephropathy characterized by severe symptomatology
at kidney level due to ultrastructural lesions of the glomerular basement membrane (GBM) as consequence of
mutations in COL4 genes. The disease has been linked to COL4A3/COL4A4/COL4A5 mutations, which impair GBM
functionality and can be inherited in a dominant, recessive or X-linked transmission. Although a targeted Next
Generation Sequencing approach has allowed identifying families with pathogenic mutations in more than one
COL4 α3-α4-α5 heterotrimer encoding genes, leading to conclude for a digenic pattern of inheritance, the role of
non-collagen genes in digenic Alport syndrome has not yet been established.
Methods: We employed a whole-exome sequencing approach on three families in whom a digenic pattern of
transmission could be suspected because of a likely biparental contribution or an unexplained phenotype in the proband.
Results: We identified in the three probands hypomorphic LAMA5 mutations co-inherited with pathogenic COL4 α4-α5
chains mutations. Segregation analysis revealed that the combination of LAMA5/COL4 variants co-segregate with a fully
penetrant phenotype in line with a digenic inheritance.
In one of the three probands an hypomorphic variant in NPHS2 was also found, suggesting that role of other kidney
disease related-genes as modifiers.
Conclusion: These findings validate the impact of LAMA5 mutations in digenic ATS and highlight the role of extracellular
matrix’s genes, basement membrane, slit diaphragm and podocyte cytoskeleton in ATS. This underline the need for a
more extensive panel approach in the presence of a digenic ATS, in order to better define clinical severity and recurrence
risk for family members.
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Background
Alport syndrome (ATS) initially described as a likely
autosomal dominant condition, with males being more
severely affected than females, [1–5] has been redefined
as an X-linked semi-dominant condition [6, 7] after the
discovery in 1990 of the causative gene COL4A5 on the
X chromosome (Xq22.3). With time it has become evident
that ATS is a genetically heterogeneous disorder for which
all three main models of Mendelian inheritance, namely
X-linked (XL), autosomal recessive (AR) and autosomal
dominant (AD), are applicable [8]. ATS is characterized by
clinical heterogeneity and extreme intrafamilial pheno-
typic variability including the degree of proteinuria, the
onset of Chronic Renal Failure (CRF), the progression-rate
to End Stage Renal Disease (ESRD), as well as the ocular
and hearing involvement. While X-linked semidominant
ATS is a well-established entity associated with mutations
in COL4A5, AR inheritance pattern is associated with two
mutations, in either COL4A3 or COL4A4 [7, 9] located on
chromosome 2(2q35-q37) [8, 10].
The existence of an AD form of ATS (ADAS) distinct
from the thin basement membrane nephropathy (TBMN)
is sometime debated; however, already in 2000, van der
Loop and colleagues provided convincing evidence in
favor of the existence of ADAS, identifying a heterozygous
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mutation in the COL4A3 gene in a large ATS family from
Northern Ireland [11]. Shortly afterwards, some ADAS
pedigrees have also been reported by our group [9] and
we have then provided clear evidence of the existence of
an AD form accounting for about a 30% of cases [12]. Re-
cently, we have reported a digenic pattern of inheritance
for ATS demonstrating that the severity of renal involve-
ment correlates with the number of the collagen type IV
mutated molecules [13, 14]. However, the digenic model
based on the combination of collagen IV mutations par-
tially explains the phenotypic variability. A recent report
underlined the contribution of LAMA5 gene mutations
co-segregating with COL4A5 mutations in patients with a
phenotypic spectrum including hematuria, proteinuria,
focal segmental glomerulosclerosis, loss of kidney function
and renal cortical cysts [15].
Here, we selected patients with a likely digenic pattern
of inheritance who presented a phenotype more severe
than what expected for a dominant ATS or for whom
family history was suggestive of a biparental inheritance
and, using a whole-exome sequencing approach, we investi-
gated whether variations in other genes of the extracellular
matrix (basement membrane and slit diaphragm) or podo-
cyte cytoskeleton are implicated in the intrafamilial pheno-
typic variability. We found that hypomorphic heterozygous
variants in LAMA5 encoding for the alpha 5 subunit of
laminin 511 segregate with the severity of renal involve-
ment sometimes along with hypomorphic heterozygous
variants in other kidney disease-related genes and we con-
cluded for more complex mechanisms of inheritance in
which non-collagen genes may play a pivotal role in disease
pathogenesis.
Methods
Patients enrollment
Genetic counselling was performed at the Medical Genetics
Unit in Siena (Azienda Ospedaliera Universitaria Senese,
AOUS) where patients with clinical criteria suggestive of
ATS, namely a positive family history and/or a indicative
kidney biopsy, high tone sensorineural hearing loss, lentico-
nus and macular flecks were selected for mutation screen-
ing in the COL4A3, COL4A4 and COL4A5 genes. Families
underwent genetic counseling and blood samples from the
probands and from their family members were collected in
EDTA-containing tubes. Patients and healthy family mem-
bers provided and signed a written informed consent at for
the use of DNA samples for diagnostic purposes.
Whole exome sequencing analysis
Paired-end exome sequencing on probands’ DNA samples
was performed by Ion Proton technology (Life Technology)
and the mutational analysis was carried on using IonTor-
rent Suite software (v.5.8.0), while post-run analysis was
conducted using Torrent Variant Caller plug-in (v5.8.0.19).
External datasets, such as 1000 genomes and ExAC, were
used to define novel variants, not previously identified.
Variants were filtered for QD (Quality by Depth) using a
cutoff of 20 reads to minimize false positive detection. All
variants were annotated using 6 different annotation
tools, namely SIFT, Polyphen, Mutation Taster, Muta-
tion Assessor, FATHMM/GERP++ combined algorithm
and LRT, to determine if the substitution was predicted
to be deleterious to protein function. For COL4A3,
COL4A4 and COL4A5 genes, according to published
guidelines [16] pathogenicity was ascertained if the follow-
ing criteria were met: non-polymorphic missense muta-
tions or in-frame deletions involving key amino acids,
such as glycine in the collagen Gly-X-Y triple helical do-
main, splice-site mutations and truncating mutations.
Pathogenicity of non-synonymous variations other than
Gly substitutions was predicted using Alamut software
V.2.11 (Interactive Biosoftware, Rouen, France). To deter-
mine whether the identified sequence variants were novel
or had been previously reported, we searched in the
dbSNP database (http://www.ncbi.nlm.nih.gov/projects/
SNP/), the Human Gene Mutation Database (http://
www.hgmd.cf.ac.uk/ac/index.php), the Leiden Open
Variation Database V.3.0 Build 35 (http://www.lovd.nl/
3.0/home) and the ALPORT (COL4A5) database
(http://www.arup.utah.edu/database/ALPORT/
ALPORT_display.php?sort = 2#alport; last update: De-
cember 2017). Three pathogenic variants were described
according to the COL4A3 reference sequence LRG_230
(NM_000091.4), COL4A4 reference sequence LRG_231
(NM_000092.4) and COL4A5 reference sequence LRG_232
(NM_000495). To select for candidate modifiers genes after
a first filtering step, we obtained for each samples an aver-
age of 85 likely protein-affecting variants (frameshift or
in-frame insertions/deletions, stopgain/stoploss variants,
splicing changes and missense variants predicted to be
damaging for at least 2/6 employed bioinformatic tools and
with a CADDphred ≥15), among which we selected for
quality (depth ≥ 20X and phred quality score ≥ 40) and for
MAF < 0.01 or unknown frequency on dbSNP151 only var-
iants lying in candidate genes encoding for the extracellular
matrix, basement membrane and slit diaphragm or podo-
cyte cytoskeleton.
Sanger sequencing and segregation analysis
Pathogenic variants identified in probands were confirmed
by Sanger sequencing using the PE BigDye Terminator
Cycle Sequencing Kit on an ABI Prism 3130 analyser (Ap-
plied Biosystems). The version 4.9 of Sequencher Software
(Genes Code Corporation, Ann Arbor, Michigan, United
States) was used for sequence analysis. Sanger sequencing
was also used to determine whether the pathogenic vari-
ants were present in family members for whom genomic
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DNA was available. Genotypes of pedigrees were exam-
ined to assess genotype-phenotype correlation.
Results
Family 1: Clinical features
The proband (IV;4) (Fig. 1, Family 1), a 22 years-old
male, presented at our outpatient clinics at 16 years of
age with constant microhematuria and proteinuria (0,3
g/dl). Kidney biopsy examination revealed thinning of
the glomerular basement membrane. Ophthalmoscopic
evaluation showed a normal fundus oculi, audiometric
evaluation was in the range of normality. At the anam-
nestic history, the parents reported macrohematuria epi-
sodes since he was 11 years old. The younger sister
(IV;5) and brother (IV;6), 13 and 10 years old, respect-
ively, at the time of the first visit displayed microhema-
turia with intermittent proteinuria identified in the
younger sister in some of the several of the 15 urine
exams viewed over the time. His mother (III;6) and her
twin sister (III;7), presented with microhematuria and
proteinuria as well. Audiometric evaluation revealed in
both cases a bilateral neurosensorial hearing loss. The
maternal grandfather (II;5) reported microhematuria and
proteinuria in association with the appearance of bilat-
eral kidney cysts at around forty-five years of age with
progression towards end stage renal disease (ESRD) at
around 50 years of age. For such reason he underwent
kidney transplantation. Bilateral neurosensorial hypoacu-
sis was also documented. The mother of the proband re-
ferred that two paternal uncles (II;2 and II;3) developed
end stage renal disease at around 45 years of age. We
evaluated the sister of the proband’s grandfather (II;4)
when she was 62 years old and she presented with
microhematuria, proteinuria and bilateral hearing loss.
Out of the two sons, the oldest (III;4), 36 years old, pre-
sented with microhematuria after physical activity while
the youngest (III;5), 25 years old, showed neither microhe-
maturia nor proteinuria. Two sons of a proband’s mater-
nal uncle (III;2 and III;3) who died for renal failure were
evaluated at the age of 54 and 51 years; urine exams were
negative for persistent microhematuria. An additional
cousin of the proband’s mother (III;1), later evaluated in
our outpatient clinics, presented with microhematuria,
proteinuria and moderate renal failure started at the age
of 40 years for which he currently undergoes dialysis.
Kidney ultrasound identified a unilateral renal cyst. No
audiometric evaluation was performed. His 15 years old
son (IV;2) presented with isolated microhematuria.
Family 1: Molecular findings
Using a whole exome sequencing approach we identi-
fied, in the proband, a heterozygous pathogenic COL4A4
mutation (exon 19:c.1109G > A:p.(Gly370Glu)) in line
with an autosomal dominant pattern of transmission. A
Fig. 1 Families pedigrees. Pedigree of the families characterized at a transcriptional level are depicted and segregation of the mutated allele/s
is reported
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thorough data examination led to identify a hypomorphic
variant in LAMA5 gene (exon 39:c.5149C >T:p.(His1717-
Tyr)). The CADDPhred of the variant is 18,73, and accord-
ing to the ExAc genomes database it has been previously
found in European populations with a frequency of 0,07/
119,590 (rs875379) (Table 1). The combination of the two
COL4/LAMA5 variants was identified in all the severely af-
fected family members while the single pathogenic COL4A4
mutation was found both in the first cousin (III;4) present-
ing with just episodic microhematuria at the age of 26 years
and in two asymptomatic individuals (III;2 and III;3), evalu-
ated at the age of 50 years, allowing us to conclude that the
COL4A4 mutation is not sufficient by itself for the pheno-
type to be displayed. An additional asymptomatic cousin
(III;5) did not harbor any of the two mutations. These find-
ings are in line with a digenic pattern of transmission as
also suggested by the average age of ESRD onset in all the
affected family members.
Family 2: Clinical features
The proband (Fig. 1, Family 2) came for the first time to
our outpatient clinics when he was 17 years old. He pre-
sented with severe microhaematuria since he was 18
months old. The anamnestic history was positive for
macrohaematuria during febrile episodes. Mild protein-
uria, in the range of 400 mg/24 was detected since he
was 13 years. Currently he is 26 years old. He displays
proteinuria in the range of 1.71 g/24 h and serum creatinine
and creatinine clearance in the upper range of normality
(1,30mg/dl and 105 cc/min, respectively). For this reason,
he is actually under treatment with RAAS-inhibitors. Kid-
ney biopsy examination revealed areas of thinning and
thickening of the glomerular basement membrane along
with podocytes foot processes fusion, compatible with clin-
ical diagnosis of ATS. Ophthalmoscopic evaluation showed
a normal fundus oculi, audiometric evaluation was normal
as well. The proband’s father, currently 53 years old,
presented microhematuria. His mother, 50 years old,
reported microhematuria since she was teenager. She
never presented with proteinuria. Audiometric evalu-
ation was negative. Kidney biopsy did not reveal any
ultrastructural alteration.
Family 2: Molecular findings
Using a whole exome sequencing approach we identified, in
the proband, a maternally inherited heterozygous pathogenic
COL4A5 mutation (exon 37:c.3319G >A:p.(Gly1107Arg)) in
line with an X-linked pattern of transmission. A thorough
data examination led to identify a hypomorphic variant in
LAMA5 gene (exon 69:c.9388C>T:p.(His3130Tyr)) The
CADDPhred of the variant is 10,66 and in European popula-
tions, the LAMA5 variant has been found with a frequency
of 0.00014 (rs201154340) (Table 1). The LAMA5 variant was
also identified in the proband’s father who presented with
microhematuria in line with a digenic pattern of transmis-
sion as also suggested by the biparental contribution.
Family 3: Clinical features
The proband (Fig. 1, Family 3) came to our outpatient
clinics when he was 15 years old. He presented with con-
stant microhematuria since he was 7 years old, no pro-
teinuria was detected in any of the urine exams in a
time span of 8 years. Kidney biopsy examination revealed
areas of thinning and thickening of the glomerular basement
membrane along with podocytes foot processes retraction
and simplification and podocytes bulging, compatible with
clinical diagnosis of ATS. Ophthalmoscopic evaluation
showed a normal fundus oculi, audiometric evaluation
displayed a mild bilateral hypoacusia since he was 12
years old. The proband’s brother was asymptomatic.
His father, 50 years old, reported microhematuria since
he was teenager. He did not presented with proteinuria.
Audiometric evaluation was positive for mild bilateral
hypoacusia. The anamnestic history was positive for
microhematuria and proteinuria in a paternal uncle who
died at 31 years of age for a gastric haemorrhage. It was
also positive for bilateral hypoacusis and ESRD in a sec-
ond paternal uncle who required kidney transplantation at
the age of 40 years.
Family 3: Molecular findings
A whole exome sequencing approach allowed us to identify,
in the proband, a heterozygous pathogenic COL4A4 muta-
tion (exon 46:c.4444del:p.(Leu1482Trpfs*70)) in line with an
autosomal dominant pattern of transmission. Data examin-
ation also led to identify two hypomorphic variant, one in
LAMA5 gene (exon 18:c.2321C >T:p.(Thr774Ile)) and the
other in NPHS2 (exon5:c.686G >A (p.(Arg229Gln)). The
CADDPrhed of the variants are 23,2 for LAMA5 and 18,73
for NPHS2, respectively (Table 1). According to the ExAc
genomes database the LAMA5 has been previously
found in European populations with a frequency of
0.001867 (rs145721906) and reported as possibly dam-
aging. According to SpliceSiteFinder-like and Human
Splicing Finder the variant, lying at − 3 nt from the GT
of the 5′ splice site consensus sequence, could also
have an impact on splicing through an alteration of the
splice donor site or an alteration of ESS and ESE sites,
respectively. However, given the low-level expression of
LAMA5 transcript in peripheral blood lymphocytes fur-
ther mRNA studies have not been performed. The
NPHS2 variant has been found with a frequency of 0,03
according to the ExAc database; however it has been
previously reported as likely pathogenic (rs61747728)
and associated with nephrotic syndrome [17]. The com-
bination of the COL4/LAMA5/NPHS2 variants was also
identified in the father while the unaffected brother
only shared the LAMA5 mutation. Unfortunately the
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proband’s uncle denied his consent to perform molecu-
lar testing.
All the clinical features, mutations in COL4 causative
genes and in the modifier genes, for the three families,
are reported in Table 1.
All the electropherograms of the mutations in COL4
causative genes and in the modifier genes, for the three
families, are reported in Additional file 1.
Discussion
ATS is one of the most common inherited form of glo-
merulopathy, often associated with deafness and ocular
lesions. Four clinical criteria, which include positive fam-
ily history of hematuria with or without chronic renal
failure, unique ultrastructural changes in the GBM, and
extrarenal manifestations for the diagnosis of ATS were
proposed by Flinter in 1988 [18]. Genetic testing is al-
ways recommended and is the only tool able to confirm
the diagnosis and define the inheritance pattern. Employ-
ing a targeted next-generation multigene panel in a clinic-
ally heterogeneous nephropathy such as ATS, we have
recently been able to define a new digenic pattern of in-
heritance with pathogenic mutations in two collagen IV
genes. However, daily clinical practice prompt us to realize
the existence of families in which a collagen-related genes
digenic pattern of inheritance is not sufficient to justify
the clinical severity, the intrafamilial variable expressivity
and sometimes the histopathological findings. Recent
works have suggested a role of other genes in exacerbating
clinical phenotype in ATS patients with COL4A5 muta-
tions [19]. Recently an association of LAMA5 and
COL4A5 variants has been described in four family mem-
bers presenting with microhematuria and proteinuria and
progressive ESRD in the spectrum of ATS [15].
For the first time, here we describe three families, two
with an apparent autosomal dominant ATS and one with
an X-linked pattern of transmission, in which a patho-
genic mutation in COL4A4 or COL4A5 cosegregate with
a likely damaging variant in LAMA5. Notably, in family
1, a very large informative family, the combination of
LAMA5/COL4A4 variants was observed in all severely
affected family members, while the single COL4A4 variant
was detected in one individual with episodic microhema-
turia and in two asymptomatic older cousins, suggesting, a
digenic inheritance rather than a modifier effect, according
to which the coexistence of both variants is necessary in
order to display all the clinical criteria for ATS diagnosis.
We have previously provided clear evidence of the exist-
ence of an AD form of Alport syndrome [12]. Here we like
to introduce the concept of a mutation type-dependent pat-
tern of transmission based on which severely damaging
COL4a3 and a4 chains mutations in heterozygous state are
sufficient to determine an autosomal dominant ATS while
hypomorphic mutations need to cosegregate together or in
association with variants in other genes of the extracellular
matrix or podocyte cytoskeleton in order for a fully pene-
trant phenotype to develop.
Previous works have shown that the glomerular filtra-
tion barrier integrity is ensured by laminin alpha5. Podo-
cytes specific inactivation of Lama5 in mice, results in
varying degrees of proteinuria and progression to neph-
rotic syndrome likely related to a thickening of the GBM
associated with podocyte foot processes disruption [20].
This is in line with the histopathological findings of the
probands in family 2 and 3 who displayed thickening
and thinning of the GBM associated with podocytes foot
processes retraction or fusion which is rarely observed
in collagen 4 genes-related ATS and that should be
regarded as a pathognomonic sign of LAMA5 variants
coinheritance. Proband’s father in family 2, harboring
the single LAMA5 mutation displays constant microhe-
maturia suggesting that damaging LAMA5 mutations in
a heterozygous state could alone explain familial
hematuria. In line with previous reports [15] renal cysts
were also observed in family 1 affected members who
harbor the combination of LAMA5/COL4A4 mutations.
These findings urge the need to investigate for a LAMA5
mutation in all ATS individuals in which kidney biopsy
is positive for the presence of renal cysts and podocytes
foot processes fusion or retraction.
In family 3 affected individuals also harbored a NPHS2
variant. The NPHS2 variant c.686G > A (p.(Arg229Gln))
(rs61747728), is reported as one of the most important
predictive factors for steroid-resistant nephrotic syn-
drome and FSGS [21]. Some studies have suggested that
a recessive inheritance of the variant is enough to deter-
mine the phenotype [22], while others have suggested
that the p.(Arg229Gln) is pathogenic only when it is
inherited in a compound heterozygote state with another
NPHS2 mutation or in combination with other variants
[23]. Our data suggests that in a heterozygote state, this
allele contributes to an oligogenic form of disease in
which any single gene plays a different role sometimes
distinct among the affected individuals. Due to the
young age of the proband at the moment of the clinical
evaluation we cannot exclude the future onset of pro-
teinuria as reported in the paternal uncle with whom he
likely shares the combination of COL4A4 mutation with
at least one of the other two variants. However, it is also
plausible to think that in each family member the exist-
ence of different trans-splicing factors would determine
a variable effect of the LAMA5 splicing variant on its
own transcript leading to a distinct clinical expressivity.
The mean age of onset of ESRD in our group of patients
harboring a combination of COL4/LAMA5 variants (II;2,
II;3, II;4; II;5 in family 1 and II;2 in family 2) is 45 years, in
line with previously reported data about collagen 4
chains-related digenic inheritance [13, 14], suggesting to
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suspect a digenic inheritance when the age of the renal
failure onset is intermediate between an autosomal dom-
inant and a recessive form. Ultimately, these data highlight
the need for a next generation sequencing approach
broadened to include non- collagen genes in order to bet-
ter define clinical severity and recurrence risk for other
family members. Definitely, a larger study which compares
patients with only a collagen 4-gene mutation and patients
harboring a combination of collagen 4/non-collagen genes
variant is needed in order to prove an additive effect of
the identified alterations.
Conclusions
In conclusion, these results reinforce the existence of a
digenic form of ATS umasking the role of non-collagen
genes, essential for the GBM formation and stabilization.
Unique pathognomonic findings from kidney biopsies
such as renal cysts and podocytes foot processes fusion or
retraction should be regarded as hallmark of a LAMA5/
COL4 variants coinheritance. Moreover, these findings
change the clinical management of patients with Alport
syndrome highlighting the importance of a NGS approach
broadened to include genes of the extracellular matrix
(basement membrane and slit diaphragm) or podocyte
cytoskeleton.
Additional file
Additional file 1: Electropherograms of the mutations in COL4 and in
the modifier genes. Electropherograms of the mutations in COL4 causative
genes and in the modifier genes, for the three families. (JPG 144 kb)
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